| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 06/03/1999 | WO1999026618A1 Skin protection composition |
| 06/03/1999 | WO1999026617A1 Use of a mixture of a diol and an alpha-hydroxy acid for the treatment of hyperkeratotic skin diseases |
| 06/03/1999 | WO1999026615A1 Cyclic amino acid derivatives as cell adhesion inhibitors |
| 06/03/1999 | WO1999026607A1 Drug delivery systems utilizing crystal structures |
| 06/03/1999 | WO1999026606A2 SUSTAINED RELEASE FORMULATIONS COMPRISING α-GLUCOSIDASE-INHIBITORS |
| 06/03/1999 | WO1999026594A1 Use of fluorinated solvents for the formulation of hair lotions |
| 06/03/1999 | WO1999026590A1 Composition for external use |
| 06/03/1999 | WO1999026582A2 Mitochondrially targeted compounds |
| 06/03/1999 | WO1999026556A1 Biodegradable intra vaginal devices |
| 06/03/1999 | WO1999018939A9 Methods of treating capsules and dry, powdered pharmaceutical formulations |
| 06/03/1999 | WO1999013913A3 High viscosity liquid controlled delivery system as a device |
| 06/03/1999 | WO1999013907A3 Methods to improve immunogenicity of antigens and specificity of antibodies |
| 06/03/1999 | WO1999011275A3 Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation |
| 06/03/1999 | WO1999007418A3 Sterile bioerodible implant device with improved biocompatability and method |
| 06/03/1999 | CA2312233A1 Preservation of sensitive biological samples by vitrification |
| 06/03/1999 | CA2311784A1 Use of fluorinated solvents for the formulation of hair lotions |
| 06/03/1999 | CA2311733A1 Proliferatively active product for treating proliferating cells |
| 06/03/1999 | CA2311498A1 Choline esters of fatty acids and their use in the treatment of stroke |
| 06/03/1999 | CA2310775A1 Mucosal delivery system comprising lipophilic thrombin inhibitors |
| 06/03/1999 | CA2309338A1 Cyclic amino acid derivatives as cell adhesion inhibitors |
| 06/02/1999 | EP0919622A2 Surface expression of enzyme in gene directed prodrug therapy |
| 06/02/1999 | EP0919231A1 Injectable parasiticide composition and process for the preparation |
| 06/02/1999 | EP0919187A1 X-Ray imaging |
| 06/02/1999 | EP0918872A1 A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
| 06/02/1999 | EP0918799A1 Amylose products as matrix former for programmed release systems, process for preparing these amylose products, and process for making programmed release systems |
| 06/02/1999 | EP0918547A2 Radiolabeled annexins |
| 06/02/1999 | EP0918546A2 Improvements in or relating to contrast agents |
| 06/02/1999 | EP0918545A2 Tumour therapy |
| 06/02/1999 | EP0918544A2 Polymer bile acid resorption inhibitors with simultaneous bile acid adsorbing effect |
| 06/02/1999 | EP0918543A2 Protein-containing polymer composition for oral administration |
| 06/02/1999 | EP0918542A2 Use of (meth)acrylic acid copolymers to increase the permeability of mucous membranes |
| 06/02/1999 | EP0918541A1 Immunstimulating lipid formulation |
| 06/02/1999 | EP0918536A1 Composition comprising insulin and insulin-like growth factor-i (igf-i) |
| 06/02/1999 | EP0918535A1 Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid |
| 06/02/1999 | EP0918510A1 Bioadhesive complexes of polycarbophil and azole antifungal or antiprotozoal drugs |
| 06/02/1999 | EP0918509A1 Biocompatible devices with foam scaffolds |
| 06/02/1999 | EP0918507A1 Aerosol formulations |
| 06/02/1999 | EP0918498A1 Improved tissue injectable composition and method of use |
| 06/02/1999 | EP0848607B1 Pharmaceutical compositions and devices for their administration |
| 06/02/1999 | EP0553176B1 Processing of yeast refuse and resulting product |
| 06/02/1999 | DE19900421A1 Viscoelastic solution for use in eye surgery |
| 06/02/1999 | DE19753298A1 Verfahren zur Herstellung von festen Dosierungsformen A process for the preparation of solid dosage forms |
| 06/02/1999 | DE19752990A1 Conjugates for targeted gene transfer |
| 06/02/1999 | CN1218411A Method of killing target cells in harvested cell populations |
| 06/02/1999 | CN1218403A Formulation for use in prevention of pathogen induced diseases including HIV and HSV |
| 06/02/1999 | CN1218396A Controlled-release pharmaceutical tablet containing carried based on cross-linked amylose and hydroxypropylmethylcellulose |
| 06/02/1999 | CN1218395A Buccal delivery system |
| 06/02/1999 | CN1218389A Personal care compositions containing copolymer having hydrophobic carbon-based grafts |
| 06/01/1999 | US5908869 Propofol compositions containing edetate |
| 06/01/1999 | US5908865 Chlorhexidine gluconate-containing, stabilized aqueous pharmaceutical preparations |
| 06/01/1999 | US5908826 Freeze-dried preparation containing monoclonal antibody |
| 06/01/1999 | US5908825 Dosage composition for nasal delivery and method of use of the same |
| 06/01/1999 | US5908824 Dispersed homogeneously in and adsorbed homogeneously onto a mucosa protecting and/or tissue repairing agent |
| 06/01/1999 | US5908757 Diagnosing by measuring complex formation of smooth muscle myosin heavy chain found in blood sample with specific antibodies; detecting increases levels |
| 06/01/1999 | US5908640 Applying a non-toxic composition of the chemical compound stannous fluoride. |
| 06/01/1999 | US5908639 Inhalation powder containing antistatic agent |
| 06/01/1999 | US5908638 Pharmaceutical compositions of conjugated estrogens and methods for their use |
| 06/01/1999 | US5908636 Polyalkylene glycol having an average molecular weight of about 400 to about 20,000 |
| 06/01/1999 | US5908631 Monohydric alcohol-free composition for topical use comprising solubilized ethylcellulose |
| 06/01/1999 | US5908629 Polysaccharide-protein complex |
| 06/01/1999 | US5908621 Polyethylene glycol modified interferon therapy |
| 06/01/1999 | US5908610 Stable microbubble suspensions comprising saturated phospholipios for ultrasonic echography |
| 06/01/1999 | CA2253700A1 The production of solid dosage forms |
| 06/01/1999 | CA2253695A1 The production of solid dosage forms |
| 05/27/1999 | WO1999025836A1 Attaching substances to micro-organisms |
| 05/27/1999 | WO1999025391A2 Biodegradable polymer scaffold |
| 05/27/1999 | WO1999025384A2 Multimeric tethered ligands and their use in receptor-ligand interactions |
| 05/27/1999 | WO1999025383A1 Conjugates comprising two active agents |
| 05/27/1999 | WO1999025382A1 Pharmaceutical combination of a cyclooxygenase-2 inhibitor |
| 05/27/1999 | WO1999025381A1 Linear antigen supporting units |
| 05/27/1999 | WO1999025349A1 Anaesthetic formulation |
| 05/27/1999 | WO1999025343A1 Granules comprising clavulanate and one or more excipients |
| 05/27/1999 | WO1999025341A1 Use of histamine for elevating blood histamine levels |
| 05/27/1999 | WO1999025338A1 Pharmaceutical composition containing zafirlukast |
| 05/27/1999 | WO1999025332A1 Composition with azelaic acid |
| 05/27/1999 | WO1999025326A1 Prolamin-plant polar lipid combination, preparation method and applications |
| 05/27/1999 | WO1999025325A1 Low temperature coatings |
| 05/27/1999 | WO1999025324A1 Administering active substances by using the capsid produced out of the polyoma virus vp1 protein |
| 05/27/1999 | WO1999025323A1 Omeprazole formulation |
| 05/27/1999 | WO1999025322A2 Pharmaceutical compositions having the shape of powders of cross-linked polymers loaded with drugs and related preparation process by supercritical fluids |
| 05/27/1999 | WO1999025208A1 Use of liquid carbohydrate fermentation product in foods |
| 05/27/1999 | WO1998007318A3 Method of making controlled release devices |
| 05/27/1999 | DE19750354A1 Covering an inductor molecule with a viral capsid, for more efficient transfection of cells |
| 05/27/1999 | CA2310462A1 Linear antigen supporting units |
| 05/27/1999 | CA2310423A1 Pharmaceutical compositions having the shape of powders of cross-linked polymers loaded with drugs and related preparation process by supercritical fluids |
| 05/27/1999 | CA2310255A1 Use of histamine for elevating blood histamine levels |
| 05/27/1999 | CA2310228A1 Attaching substances to micro-organisms |
| 05/27/1999 | CA2310138A1 Prolamin-plant polar lipid combination, preparation method and applications |
| 05/27/1999 | CA2309858A1 Use of liquid carbohydrate fermentation product in foods |
| 05/27/1999 | CA2272402A1 Granules comprising clavulanate and one or more excipients |
| 05/26/1999 | EP0917880A1 Inclusion complex of diiodomethyl-p-tolylsulfone with cyclodextrin derivatives |
| 05/26/1999 | EP0917879A2 Procédé amélioré pour la stabilisation des protéines |
| 05/26/1999 | EP0917875A1 Aqueous eye drops containing apafant as principal agent |
| 05/26/1999 | EP0917872A1 A composition for delivering drug by ionotophoresis |
| 05/26/1999 | EP0917871A2 Cosmetic and pharmaceutical compositions comprising ascorbic acid derivatives |
| 05/26/1999 | EP0917869A2 Use of water-in-oil emulsions as thickening agents in cosmetical and pharmaceutical compositions |
| 05/26/1999 | EP0917570A2 Mhc binding peptide oligomers and methods of use |
| 05/26/1999 | EP0917473A1 Covalent polar lipid conjugates with biologically-active compounds for use in salves |
| 05/26/1999 | EP0917472A1 Antiprotozoal composition |
| 05/26/1999 | EP0917460A1 Cyclosporin formulation |